immune system
|
• mild splenomegaly
|
|
• mild decrease of CD8+ T cell percentage in spleen and bone marrow
|
homeostasis/metabolism
|
• after treatment with anti-Fas antibody
|
|
• after treatment with anti-Fas antibody
|
cellular
|
• resistance to apoptosis in mouse dermal fibroblasts (MDFs) after treatment with RIPK3 kinase inhibitor GSK872 in vitro
• compromised apoptosis in thymocytes in vitro and increased survival in vivo after treatment with anti-Fas antibody
|
hematopoietic system
| N |
• normal B cells and myeloid cells in spleen, lymph nodes and bone marrow
|
|
• mild splenomegaly
|
|
• mild decrease of CD8+ T cell percentage in spleen and bone marrow
|
growth/size/body
|
• mild splenomegaly
|
mortality/aging
| N |
• viable
|


Analysis Tools